Ferrer has acquired the rights to distribute United Therapeutics’ Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China. Terms of the deal were not disclosed.
Tyvaso inhalation solution is currently approved for the treatment of PH-ILD only in the US. Ferrer said that the company “is now working with health authorities to determine the appropriate regulatory pathway to obtain approval for this product . . . for the treatment of PH-ILD in other territories.”
Ferrer CEO Mario Rovirosa said, “This is an important milestone for Ferrer, a B Corp company. As a company, we aim to deliver the best possible solutions to underserved patients around the globe by promoting a new way of doing business and approaching the world.”
United Therapeutics President and Chief Operating Officer Michael Benkowitz commented, “We’re proud of our strong and lasting relationship with Ferrer, and this distribution agreement has the potential to bring Tyvaso to PH-ILD patients in need worldwide, who currently have no other treatment options. Having recently converted into a public benefit corporation ourselves, we applaud and share Ferrer’s patient-driven mission – underscored by its recent B Corp certification.”
Read the Ferrer press release.
